Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Patent Office (EPO) has granted Patent No 1725233 for Sunesis Pharmaceuticals, claiming the company's pharmaceutical compositions of drug candidate Vosaroxin.
Subscribe to our email newsletter
Vosaroxin, formerly known as voreloxin, is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer.
Vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis.
Sunesis is proceeding to validate the patent in multiple EPO member states.
The resulting national patents would expire on 14 March 2025, but could be eligible for patent term extension beyond the date.
A related US patent was granted in 2010, and related patent applications are pending in other markets throughout the world including Japan, Australia and Canada.
Sunesis CEO Daniel Swisher said this patent is an important new addition to their intellectual property estate, as it covers the formulation currently used in their pivotal Phase 3 VALOR trial in relapsed/refractory Acute Myeloid Leukemia (AML).
"Supplementing protection for our vosaroxin development program with new patents having life out to 2025 increases not only the value of our AML franchise but also provides sufficient time for lifecycle evaluation of vosaroxin in other indications," Swisher said.